Updates are available Correction dated 2024-11-07
Click to view Correction: https://doi.org/10.1186/s12959-024-00670-z
-
Authors
Lorentsson, Hans Johan Niklas
Clausen, Christina R.
Faurholt-Jepsen, Daniel
Hansen, Katrine Bagge
Jensen, Sidse Graff
Krogh-Madsen, Rikke
Hagelqvist, Per G.
Johansson, Pär I.
Vilsbøll, Tina
Knop, Filip K.
Ravn, Pernille
-
Funding
Funding for this research was provided by:
Copenhagen University
- License Information
-
More Information
Article History
Received: 28 February 2024
Accepted: 19 June 2024
First Online: 26 June 2024
Change Date: 7 November 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12959-024-00670-z
Declarations
:
: The studies were conducted in accordance with the Declaration of Helsinki and approved by the local Scientific and Ethical Committee (H-20028894, H-19025674), the Danish Medical Agency (2020-001173-69) and the Danish Data Protection Agency (P-2020-309, P-2020-847).
: Not applicable.
: H.J.N.L. and P.R. have received Quantiferon-TB Gold plus assays as a gift from SSI diagnostica for another project. T.V. has served on scientific advisory panels, been part of speaker’s bureaus, served as a consultant to and/or received research support from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Gilead, GSK, Novo Nordisk, Sanofi and Sun Pharmaceuticals. F.K.K. has served on scientific advisory panels and/or been part of speaker’s bureaus for, served as a consultant to and/or received research support from, and/or has shares in, Antag Theurapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Gubra, Novo Nordisk, Sanofi, Zealand Pharma and is currently employed by Novo Nordisk. P.R. has a patent on IP-10 as a diagnostic tool for TB. The remaining authors have nothing to disclose and all authors declare that the research was conducted in the absence of any potential conflict of interest.
